DIVISLAB Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > divislab

Technical Analysis

Technical Strength: 6.9 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 71.9. According to RSI analysis, divislab is overbought. 3.0 DIVISLAB RSI Chart
MACD (?) MACD: 32.7 and Signal Line: 26.7. According to MACD analysis, divislab is technically strong. 8.0 DIVISLAB MACD Chart
Simple Moving Average (?) According to simple moving average analysis, divislab is in a strong uptrend. Major support levels are 1121.697, 1069.24, 939.3637. 10.0 DIVISLAB Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, divislab is in a strong uptrend. Major support levels are 1131.567, 1092.354, 984.5482. 10.0 DIVISLAB Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.907. According to bollinger bands, divislab is technically strong. 7.0 DIVISLAB Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 1135.1175 and 1114.025. Resistance level is 1203.4. 6.5 DIVISLAB Fibonacci Retracement Chart
Average True Range (?) ATR: 32.3 NA DIVISLAB Average True Range Chart
Average Directional Index (?) ADX is 36.1 which means DIVISLAB is in a trend. NA DIVISLAB Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
April 20, 2018
Open Price 1175.7
High Price 1199.0
Low Price 1167.6
Close Price 1194.25
Absolute Change 14.5
Percentage Change 1.23%
Weekly Change 4.26%
Monthly Change 9.97%
Yearly Change 86.6%
52-week high 1203.4
52-week low 532.65
Corporate Actions
ExDate Purpose
September 15, 2017 AGM/DIV-RS 10/- PER SHARE
August 18, 2016 ANNUAL GENERAL MEETING
March 17, 2016 INT DIV-RS 10 PER SHARE
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.577
Confidence in Beta2.24%
Market Capital Rs. 31703.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 41.73
TTM Price-to-Earnings (P/E) Ratio 28.6
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 20 April 2018: Deliverable Quantity:7.16e+04 NA DIVISLAB Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 20 April 2018: Daily Volatility:0.2866 NA DIVISLAB Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 20 April 2018: PCR_OI:0.442 PCR:0.351 NA DIVISLAB PCR Chart
Option Pain (?) 20 April 2018: Max Pain:1150.0 NA DIVISLAB Option Pain Chart
Premium (?) 20 April 2018 Premium: 1.45 Futures OI:2163200.0 NA DIVISLAB Premium Chart
Option_MAX_OI (?) 20 April 2018: Price:1194.25 Put with maximum OI:1100.0 Call with maximum OI:1200.0 NA DIVISLAB Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
April 26, 2018 1195.7 2163200.0 1245.0 1318.0 1194.25
May 31, 2018 1201.25 246400.0 157.0 160.0 1194.25

Announcements

April 09, 2018 DrDisc. under Reg.30 of SEBI (SAST) Reg.2011r. Murali K. Divi has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
November 01, 2017 DiOutcome of Board Meetingivi's Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 31, 2017.
See all Announcements

Board Meetings

Date Meeting Date Purpose
January 18, 2018 January 27, 2018 ToResultso consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2017.
October 23, 2017 October 31, 2017 ToResultso consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended September 30, 2017.
See all Board Meetings

DIVISLAB is part of...

Index Weightage
NFTYMCAP50 NA
CNXPHARMA NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 1144 Rs. 1156 Rs. 1175 Rs. 1187 Rs. 1206 Rs. 1218 Rs. 1238